

AWARD NUMBER: W81XWH-14-1-0120

TITLE: Temporal Changes in FLT3-ITD Regulation of Stem Cell Self-Renewal and Leukemogenesis

PRINCIPAL INVESTIGATOR: Jeffrey A. Magee

**CONTRACTING ORGANIZATION: Washington University
St. Louis, MO 63110**

REPORT DATE: September 2015

TYPE OF REPORT: Annual

**PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**

**DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited**

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE September 2015		2. REPORT TYPE Annual		3. DATES COVERED 1 Sept 2014 - 31 Aug 2015	
4. TITLE AND SUBTITLE Temporal Changes in FLT3-ITD Regulation of Stem Cell Self-Renewal and Leukemogenesis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-14-1-0120	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dr. Jeffrey Magee E-Mail: magee_j@kids.wustl.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Washington University St. Louis, MO 63110				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT My goal is to understand how mechanisms that regulate normal hematopoietic development can also influence the mutation spectra of pediatric and adult acute myeloid leukemia (AML). Genetic differences between pediatric and adult AML may underlie differences in outcomes and necessitate different treatment strategies, yet we have few insights into why these differences occur. To address this problem, we are testing whether one mutation, FLT3-ITD, differentially regulates fetal and adult progenitors. FLT3-ITD mutations are more common in adult AML than in childhood AML, and our studies to date have shown that it has age-specific phenotypes. In adult mice, FLT3-ITD depleted the hematopoietic stem cell (HSC) pool and expanded myeloid progenitor populations. These phenotypes were not evident in fetal mice, even in the presence of a collaborating <i>Runx1</i> mutation. To understand why fetal and adult progenitors responded differently to FLT3-ITD, we characterized signal transduction (e.g. STAT5 and MAPK pathways) in fetal, neonatal and adult progenitors. STAT5 was activated by FLT3-ITD at all stages of development, but MAPK was activated only in post-natal progenitors. Furthermore, STAT5 target gene regulation changed through the course of development. We are now testing whether reactivation of fetal gene products can suppress leukemogenesis. Reprogramming therapies may offer a novel approach for treating AML.					
15. SUBJECT TERMS FLT3-ITD, leukemia, hematopoietic stem cell					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 10	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments.....	4-7
4. Impact.....	7
5. Changes/Problems.....	8
6. Products.....	8-9
7. Participants & Other Collaborating Organizations.....	9-10
8. Special Reporting Requirements.....	10
9. Appendices.....	10

1. INTRODUCTION

The goal of this project is to understand why FLT3-Internal Tandem Duplication (*FLT3-ITD*) mutations cause acute myeloid leukemia (AML) more frequently in adults than in children. *FLT3-ITD* encodes a constitutively active FLT3 tyrosine kinase. This mutation occurs in ~30% of adult AML, but only 5-10% of pediatric AML and <1% of infant AML. This suggests that the mutation preferentially transforms older progenitors. To test whether FLT3-ITD has age-specific effects on hematopoietic stem cells (HSCs) and other hematopoietic progenitors, we have been characterizing its function in fetal, neonatal and adult mouse HSCs. Thus far, we have found that FLT3-ITD differentially regulates fetal and adult HSCs. Furthermore, it induces age-specific changes in signal transduction and gene expression in HSCs and more committed progenitors. We are now testing whether fetal specific gene products can re-program adult progenitors and blunt leukemogenesis. Reprogramming therapies offer a novel approach for treating AML.

2. KEYWORDS

- Flt3-Internal Tandem Duplication (FLT3-ITD)
- Hematopoietic stem cell (HSC)
- Acute myeloid leukemia
- Stat5
- MAP-kinase

3. ACCOMPLISHMENTS

Major goals:

Aim 1: To test whether *FLT3-ITD* depletes HSCs, expands restricted progenitors and promotes a myeloproliferative neoplasm during the adult, but not fetal stage of development.

Aim 2: To test whether fetal and adult hematopoietic progenitors have different FLT3-ITD driven signal transduction mechanisms and gene expression.

Aim 3: To test whether ectopic *Lin28b* expression impedes FLT3-ITD driven HSC depletion and leukemogenesis.

Accomplishments under these goals:



Aim 1: To test whether *FLT3-ITD* depletes HSCs, expands restricted progenitors and promotes a myeloproliferative neoplasm during the adult, but not fetal stage of development.

All of the proposed experiments related to this aim have been accomplished:

My lab used knock-in mice to test whether *FLT3-ITD* has age-specific effects on HSC self-renewal, myelopoiesis, signal transduction and gene expression. We found that *FLT3-ITD* caused a marked reduction in adult HSCs (CD150⁺CD48⁻Lineage⁻c-Kit⁺Sca1⁺), consistent with prior studies, yet it had no effect on fetal HSC numbers (Fig. 1A, B). In limiting dilution transplants the mutation impaired reconstitution of the blood system by adult bone marrow, but it did not affect reconstitution by fetal liver cells (Fig. 1C, D). *FLT3-ITD* began to deplete the HSC pool by 14 days after birth in mice (Fig. 1E). Expansion of the myeloid progenitor pool and myeloproliferative neoplasms (MPN) were also evident in 14 day old *FLT3-ITD* mice but not fetal mice (Fig. 1F and not shown). *FLT3-ITD*

therefore depletes the HSC pool and induces myeloid expansion only in a post-natal developmental context.

Since *FLT3-ITD* collaborates with other mutations to drive AML, we tested whether it has age-specific phenotypes in the presence of collaborating *Runx1* mutations. Mono- and bi-allelic *Runx1* mutations are found in human *FLT3-ITD* positive AML, and they are more common in adults than children. We generated mice with *FLT3-ITD*; *Runx1* compound mutations (*Vav-Cre*; *FLT3*^{ITD/+}; *Runx1*^{f/+}) and analyzed HSC, multi-potent progenitor (MPP; CD48⁺LSK) and myeloid progenitor frequencies at post-natal day (P)0, P14 and P21. We also analyzed spleen histology and blood cell morphology. We focused on the effects of compound heterozygous mutations because most *Vav-Cre*; *Runx1*^{f/f} mice died shortly after birth, irrespective of their *FLT3-ITD* status and without evidence of leukemia (data not shown), and because *Runx1* deficiency alters HSC surface marker phenotypes. *Vav-Cre*; *FLT3*^{ITD/+}; *Runx1*^{f/+} mice survived post-natally. All developed enlarged spleens with MPN by P14, and some developed AML around 3 months after birth (data not shown). The bone marrow of *Vav-Cre*; *FLT3*^{ITD/+}; *Runx1*^{f/+} mice was severely depleted of phenotypic HSCs at P14 and P21, and the MPP population was expanded (Fig. 2). In contrast, newborn (P0) *Vav-Cre*; *FLT3*^{ITD/+}; *Runx1*^{f/+} mice had normal liver sizes, normal HSC numbers and only a mild increase in MPPs (Fig. 2). *FLT3-ITD* therefore has distinct effects on pre- and post-natal hematopoiesis even in the setting of a collaborating *Runx1* mutation.



Aim 2: To test whether fetal and adult hematopoietic progenitors have different *FLT3-ITD* driven signal transduction mechanisms and gene expression.

All of the proposed experiments related to this aim have been accomplished:

To understand why *FLT3-ITD* has distinct effects on pre- and post-natal hematopoiesis, we evaluated signal transduction and gene expression at E14.5, P0, P14 and 8 weeks after birth. The *FLT3-ITD* protein has previously been shown to activate the STAT5, MAP-kinase (MAPK) and PI3-

kinase (PI3K) pathways in cultured cells. In mice, the mutation did not hyper-activate the PI3K pathway, and mTORC2 (a PI3K pathway effector) was not necessary for *FLT3-ITD* mediated HSC depletion or MPN (data not shown). In contrast, the STAT5 and MAPK pathways had distinct, age-specific activities in *FLT3-ITD* HSCs (Fig. 3A). STAT5 was hyper-activated in *FLT3-ITD* HSCs at all evaluated stages of development, but the MAPK pathway (as shown by ERK1/2 phosphorylation) was hyper-activated only in P14 and adult *FLT3-ITD* HSCs (Fig. 3A). To test whether STAT5 inactivation rescued HSC depletion and MPN, we conditionally deleted *Stat5a/b* in compound mutant *Mx1-Cre; FLT3^{ITD/+}; Stat5a/b^{f/f}* and *Mx1-Cre; FLT3^{ITD/+}; Stat5a/b^{f/f}* mice. To our surprise, *Stat5a/b* deletion exacerbated HSC depletion and myeloid progenitor expansion rather than rescuing these phenotypes (Fig. 3B, C), and this was associated with a more severe MPN (data not shown). Functional studies of the MAPK pathway are in progress, but the data already suggest that STAT5 helps to maintain *FLT3-ITD* mutant progenitors in an immature state even as other effectors promote myeloid commitment. It is now important to understand which *FLT3-ITD* target genes promote normal and neoplastic self-renewal, which genes remain active in fully transformed AML cells and how normal developmental programs shape the *FLT3-ITD* transcriptome.

To understand how *FLT3-ITD* target gene regulation changes with age, we used microarrays to characterize gene expression in wild type and *FLT3^{ITD/+}* HSCs and MPPs at E14.5, P0, P14 and 8 weeks after birth. To determine which *FLT3-ITD* targets are regulated via STAT5, we also characterized gene expression in wild type, *FLT3^{ITD/+}*, *FLT3^{ITD/ITD}*, *Mx1-Cre; FLT3^{ITD/+}; Stat5a/b^{f/f}* and *Mx1-Cre; FLT3^{ITD/+}; Stat5a/b^{f/f}* adult MPPs. These experiments made several key points: 1) In wild type HSCs, most fetal-specific genes are inactivated and most adult-specific genes are activated between birth and P14. This is earlier than prior studies have suggested, and it correlates with the age at which *FLT3-ITD* induces HSC depletion and myeloid expansion (Fig 4A, B for representative examples). 2) *FLT3-ITD* does not alter gene expression until

after birth, coincident with onset of the HSC depletion and myeloid expansion phenotypes (Fig. 4C). 3) *FLT3-ITD* target genes are more differentially expressed in MPPs than in HSCs (Fig. 4E, F), consistent with recent data suggesting that MPPs are a cell of origin for *FLT3-ITD* driven AML. 4) Most, but not all, *FLT3-ITD* target genes are STAT5 dependent (Fig. 4D). Functional studies are now necessary to identify novel, adult specific effectors of *FLT3-ITD* driven leukemogenesis (Aim 1) and to determine whether fetal genetic programs can suppress leukemogenesis (Aim 2). The over-arching goal is to understand whether AML cells exhibit “context addiction” (i.e. a sustained requirement for normal adult gene products and a toxic response to fetal gene products) that can be exploited therapeutically.




Figure 3. *FLT3-ITD* activated STAT5 at all ages but MAPK only in adult HSCs, and STAT5 maintained *FLT3-ITD* HSCs. (A) Western blots showing STAT5 and MAPK activation in control and *FLT3-ITD* HSCs during different stages of pre- and post-natal development. (B, C) HSC depletion (B) and MPP expansion (C) was enhanced in *FLT3-ITD* mice by deleting one or both *Stat5a/b* alleles. * $P < 0.05$, # $P < 0.01$ relative to wild type.




Figure 4. Developmental and *FLT3-ITD* target gene expression. (A, B) *H19* and *Egr1* are representative of many genes that are expressed higher (A) or lower (B) in adult HSCs as compared to fetal HSCs. Differential expression is clearly evident by P14. (C) *FLT3-ITD* target genes are largely activated or repressed beginning at P14. (D-F) A majority of *FLT3-ITD* targets are regulated by STAT5. Two examples are *Socs2* (E) and *Rab44* (F). (G) *Rab44* is an example of a *FLT3-ITD* target that is expressed higher in AML as compared to benign hematopoietic cells.

Aim 3: To test whether ectopic *Lin28b* expression impedes *FLT3-ITD* driven HSC depletion and leukemogenesis.

We are in the process of conducting these experiments as outlined in the statement of work. We have generated *FLT3-ITD*; *iLin28b* compound mutant mice and we have begun to analyze HSC frequencies in adulthood.

Opportunities for training and professional development:

This work was selected for an oral presentation at the International Society for Stem Cell Research (ISSCR) annual meeting. While at the meeting, I participated in a young investigator session as well as several additional speaker symposia. I have attended both the American Society for Hematology annual meeting and the ISSCR annual meeting in the past year. I interact with my primary mentor on this proposal, Sean Morrison, several times a year at meetings, and I plan to go to Dallas and present my work to his lab in October.

Dissemination of results to communities of interest:

Thus far, I have presented the work as an oral presentation at the ISSCR meeting. We are preparing a manuscript based on results from aims 1 and 2.

Plans for the next reporting period to accomplish the goals:

We will continue the experiments from aim 3 as outlined in the Statement of Work. This project is ahead of schedule. These plans will include further characterization of *FLT3-ITD*; *iLin28b* compound mutant mice and *FLT3-ITD*; *iLin28b*; *Runx1^{FL/+}*; *Ubc-CreER* mice.

4. IMPACT

Impact on the development of the principal discipline of the project:

When published, this project will provide the first evidence that leukemia causing mutations can have age-specific effects on blood forming stem cells and other immature blood cells. This likely contributes to the differences between pediatric and adult leukemias, and It raises the possibility of targeting developmental programs to suppress leukemogenesis.

Impact on other disciplines:

Nothing to report.

Impact on technology transfer:

Nothing to report.

Impact on society beyond science and technology:

Nothing to report.

5. CHANGES/PROBLEMS:

Changes in approach/reasons:

Nothing to report.

Actual or anticipated problems or delays and actions or plans to resolve them:

Nothing to report.

Changes that had a significant impact on expenditures:

Nothing to report.

Significant changes in the use or care of human subjects:

Nothing to report.

Significant changes in the use or care of vertebrate animals:

Nothing to report.

Significant changes in the use of biohazards and/or select agents:

Nothing to report.

6. PRODUCTS

Publications:

Nothing to report.

Books or one-time publications:

Nothing to report.

Other publications:

Nothing to report.

Websites:

Nothing to report.

Technologies and techniques:

Nothing to report.

Inventions, patent applications or licenses:

Nothing to report.

Other products:

Nothing to report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**Individuals who have worked on this project:**

Name:	Jeffrey Magee, M.D., Ph.D.
Project role	PI
Nearest person month worked	4
Contribution to Project	Dr. Magee oversees the entire research effort including the design, conduct and interpretation of experiments. He also performs experiments.
Funding Support - besides DOD	St. Baldrick's Foundation, Hyundai Hope on Wheels

Name:	Shaina Porter, Ph.D.
Project role	Post-doctoral fellow
Nearest person month worked	3
Contribution to Project	Dr. Porter designs, conducts and interprets experiments under the guidance of the PI. She has conducted the experiments related to temporal changes in FLT3-ITD regulation of HSCs and the signal transduction and gene expression studies.
Funding Support - besides DOD	Hyundai Hope on Wheels

Name:	Jenna Voightmann
Project role	Research technician
Nearest person month worked	6
Contribution to Project	Ms. Voightmann managed the mouse colony and assisted with experiments.
Funding Support - besides DOD	St. Baldrick's Foundation and institutional funds.

Name:	Andrew Cluster, M.D.
Project role	Clinical Fellow
Nearest person month worked	2
Contribution to Project	Dr. Cluster has characterized the FLT3-ITD; Runx1 compound mutant
Funding Support - besides DOD	Departmental support of clinical trainees- graduate medical education support.

Changes in active other support of the PD/PUI or senior key personnel:

Nothing to report.

Other organizations that were involved as partners:

Nothing to report.

8. SPECIAL REPORTING REQUIREMENTS

Nothing to report.

9. APPENDICES

None.